The European Medicines Agency (EMA) has approved two additional manufacturing sites for the Pfizer/BioNTech Covid-19 vaccine.
The sites are located in Reinbek, Germany (operated by Allergopharma GmbH & Co KG) and Stein, Switzerland (operated by Novartis Pharma).
The EMA's committee for human medicines (CHMP) announced the approval on Tuesday, with the new sites expected to support the continued supply of the Pfizer vaccine in the EU.
EMA has approved additional manufacturing sites for the production of Comirnaty, the #COVID19vaccine developed by BioNTech and Pfizer. https://t.co/kFXSVB6rRn#VaccinesWork #CovidVaccines pic.twitter.com/sKSBaBkrzu
— EU Medicines Agency (@EMA_News) June 22, 2021
A statement released by the EMA said the decision does not require approval from the European Commission and "the sites can become operational immediately".
